Pharma_88
☆    

India,
2020-11-27 14:51
(1216 d 19:51 ago)

Posting: # 22089
Views: 1,422
 

 Orlistat EMA [Design Issues]

Dear All,

This is regarding Orlistat for EMA submission. We have US product specific guidance available but I am unable to find EMA guidance (most probably its not there).

My question is whether is it required to add third arm (The reference product at 2 x 60 mg or 120 mg tid) as per US OGD for EMA? whether regualotry will accept this design as per FDA or 2WCO is sufficient (The test & reference product at 60 mg tid as crossover)?

thanks.
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,639 registered users;
85 visitors (0 registered, 85 guests [including 8 identified bots]).
Forum time: 10:42 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5